Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Guardant Health, Inc.

GH ✓ COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Medical Equipment, Supplies & Distribution ·

USA Large Cap Analyst: BUY

Last Close

$157.38

▼ -1.04%

Market Cap $21.12B · Vol 252.75K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$21.12B

Large Cap

Div Yield

N/A

EPS Growth

+53.64%

YoY

RSI (14)

34.84

Momentum

Beta

1.60

vs Market

52W High

$176.26

10.71% below

52W Low

$53.44

194.50% above

Volume

252.75K

Avg 574.97K

P/B

N/A

Price-to-book

ROE

348.42%

Return on equity

Free Float

95.48%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Guardant Health, Inc. (GH) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GH pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.27%

-4.67%

+20.23%

+78.78%

YTD

+54.08%

+177.10%

+384.25%

+21.91%

Financials & Valuation

TTM · Annual

Total Revenue	$982.02M
Net Income	$-416,277,000.00
Revenue Growth (YoY)	+44.33%
Gross Margin	64.46%
Operating Margin	-44.53%
Net Profit Margin	-42.39%
ROE	348.42%
ROA · ROIC	-23.86% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	13.04
P/B	N/A
P/FCF	N/A
EPS Growth	+53.64%
Outstanding Shares	134.20M

Technical Indicators

50-Day SMA	$159.85
200-Day SMA	$118.58
RSI (14)	34.84
Beta	1.60
52-Week High	$176.26
52-Week Low	$53.44

Volume Today	252.75K
Avg Daily Volume (30D)	574.97K
Relative Volume	0.44x
Volatility (10D)	30.43
Volatility (30D)	42.80
Free Float	95.48%

Analyst Consensus

BUY

Current Price $157.38

Mean Target $192.54

52W Low$53.44 52W High$176.26

Current

Target

$53.44 $176.26

Current Analyst target

+22.34% upside potential · 28 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG006D97VZ8

ISINUS40131M1099

CountryUSA

Sub-IndustryLaboratory Diagnostic & Testing Substances

Earnings DateOct 27, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

BIM.PA Biomerieux SA -1.68% TXG 10x Genomics, Inc. +3.33% CAI Caris Life Sciences, Inc. +1.25% LNTH Lantheus Holdings, Inc. -0.14% 300832.SZ Shenzhen New Industries Biomedical Engineering Co Ltd +0.00%

Company Profile

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.